{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:35:54Z","timestamp":1760056554789,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.det.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T08:02:09Z","timestamp":1564473729000},"page":"443-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnosis and Management of Cutaneous B-Cell Lymphomas"],"prefix":"10.1016","volume":"37","author":[{"given":"Stephen J.","family":"Malachowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Seminario-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2019.05.004_bib1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V99.3.800","article-title":"Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients","volume":"99","author":"Fink-Puches","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2019.05.004_bib2","doi-asserted-by":"crossref","first-page":"329.e1-13","DOI":"10.1016\/j.jaad.2013.06.011","article-title":"Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification","volume":"69","author":"Su\u00e1rez","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2019.05.004_bib3","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2019.05.004_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cll.2017.05.009","article-title":"Primary cutaneous B-cell lymphomas","volume":"37","author":"Hope","year":"2017","journal-title":"Clin Lab Med"},{"issue":"10","key":"10.1016\/j.det.2019.05.004_bib5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","article-title":"Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States","volume":"28","author":"Wood","year":"2001","journal-title":"J\u00a0Cutan Pathol"},{"issue":"9","key":"10.1016\/j.det.2019.05.004_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","article-title":"Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland","volume":"24","author":"Goodlad","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.det.2019.05.004_bib7","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/00000478-199711000-00005","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma","volume":"21","author":"Cerroni","year":"1997","journal-title":"Am J Surg Pathol"},{"year":"2018","series-title":"Clinical practice guidelines in oncology, Primary Cutaneous B-cell Lymphomas version 2.2018","key":"10.1016\/j.det.2019.05.004_bib8"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2008.07159.x","article-title":"Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma","volume":"142","author":"Senff","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.det.2019.05.004_bib11","doi-asserted-by":"crossref","first-page":"343.e1-11","DOI":"10.1016\/j.jaad.2013.06.011","article-title":"Primary cutaneous B-cell lymphomas: part 2. Therapy and future directions","volume":"69","author":"Su\u00e1rez","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.semdp.2016.11.007","article-title":"Cutaneous marginal zone lymphomas","volume":"34","author":"Swerdlow","year":"2017","journal-title":"Semin Diagn Pathol"},{"issue":"21","key":"10.1016\/j.det.2019.05.004_bib13","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.det.2019.05.004_bib14","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the italian study group for cutaneous lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.det.2019.05.004_bib15","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.det.2019.05.004_bib16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1634\/theoncologist.2015-0175","article-title":"Primary cutaneous B-cell lymphoma: management and patterns of recurrence at the multimodality cutaneous lymphoma Clinic of The Ohio State University","volume":"20","author":"Haverkos","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.det.2019.05.004_bib17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00000478-200308000-00003","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases","volume":"27","author":"Li","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.det.2019.05.004_bib18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199608000-00010","article-title":"Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients","volume":"20","author":"Bailey","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2133.2000.03609.x","article-title":"Multiple cutaneous immunocytoma with secondary anetoderma: a report of two cases","volume":"143","author":"Child","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2559.1993.tb00469.x","article-title":"Cutaneous immunocytomas: a clinicopathologic study of 26 cases","volume":"23","author":"Rijlaarsdam","year":"1993","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.det.2019.05.004_bib21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-4362.1990.tb03469.x","article-title":"Clinicopathologic study of cutaneous plasmacytoma","volume":"29","author":"Torne","year":"1990","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.12788\/j.sder.2018.014","article-title":"Primary cutaneous B-cell lymphomas\u2014 clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Chen","year":"2018","journal-title":"Semin Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2133.2003.05649.x","article-title":"Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib24","first-page":"12","article-title":"Primary cutaneous B-cell lymphomas","volume":"10","author":"Kempf","year":"2012","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.det.2019.05.004_bib25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-2133.2001.04128.x","article-title":"Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma","volume":"144","author":"Child","year":"2001","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.det.2019.05.004_bib26","first-page":"1207","article-title":"Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy","volume":"14","author":"Nicolay","year":"2016","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib27","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1177\/229255031101900208","article-title":"Primary cutaneous B-cell lymphoma: Role of surgery","volume":"19","author":"Parbhakar","year":"2011","journal-title":"Can J Plast Surg"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2133.2012.10902.x","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma","volume":"167","author":"Pe\u00f1ate","year":"2012","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2019.05.004_bib31","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1080\/10428190802258923","article-title":"Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study","volume":"49","author":"Maza","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/mt.2010.52","article-title":"Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas","volume":"18","author":"Dummer","year":"2010","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib34","doi-asserted-by":"crossref","first-page":"e83670","DOI":"10.1371\/journal.pone.0083670","article-title":"TG1042 (Adenovirus-interferon-\u03b3) in primary cutaneous B-cell lymphomas: a phase II clinical trial","volume":"9","author":"Dreno","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.semdp.2016.11.006","article-title":"Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma","volume":"34","author":"Hope","year":"2017","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2133.2009.09121.x","article-title":"Juvenile onset of primary low-grade cutaneous B-cell lymphoma","volume":"161","author":"Amitay-Laish","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.004_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.0736-8046.2004.21500.x","article-title":"The spectrum of cutaneous lymphomas in patients less than 20 years of age","volume":"21","author":"Fink-Puches","year":"2004","journal-title":"Pediatr Dermatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.det.2019.05.004_bib38","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaad.2004.05.025","article-title":"Primary cutaneous follicular center cell lymphoma of the nose with maxillary sinus involvement in a pediatric patient","volume":"52","author":"Ghislanzoni","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jaad.2012.02.033","article-title":"World Health Organization\u2013European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: A retrospective study at a single tertiary institution","volume":"67","author":"Park","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2019.05.004_bib40","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood.V95.12.3922","article-title":"Primary cutaneous follicle center cell lymphoma with follicular growth pattern","volume":"95","author":"Cerroni","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00000478-200206000-00006","article-title":"Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity","volume":"26","author":"Goodlad","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.det.2019.05.004_bib42","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/1097-0142(19910501)67:9<2311::AID-CNCR2820670918>3.0.CO;2-0","article-title":"Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases","volume":"67","author":"Santucci","year":"1991","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.1523-1747.2002.01785.x","article-title":"Inactivation of tumor suppressor genes p15INK4b and p16INK4a in primary cutaneous B cell lymphoma","volume":"118","author":"Child","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.0022-202X.2004.22720.x","article-title":"Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas","volume":"123","author":"Hallermann","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00000372-200402000-00002","article-title":"Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern","volume":"26","author":"Leinweber","year":"2004","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1346-8138.2010.01049.x","article-title":"Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008","volume":"38","author":"Fujita","year":"2011","journal-title":"J\u00a0Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.004_bib47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clml.2012.06.010","article-title":"Age, race, sex, stage, and incidence of cutaneous lymphoma","volume":"12","author":"Wilson","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.det.2019.05.004_bib48","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/00000478-200312000-00006","article-title":"Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes","volume":"27","author":"Goodlad","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"16","key":"10.1016\/j.det.2019.05.004_bib49","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","article-title":"Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study","volume":"19","author":"Grange","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.det.2019.05.004_bib50","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the\u00a0legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.det.2019.05.004_bib51","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.det.2019.05.004_bib52","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jid.2016.04.018","article-title":"MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma","volume":"136","author":"Menguy","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"11","key":"10.1016\/j.det.2019.05.004_bib53","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.det.2019.05.004_bib54","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/modpathol.3800650","article-title":"Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma","volume":"19","author":"Hoefnagel","year":"2006","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.det.2019.05.004_bib55","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1309\/AJCP4SUBR4NPSPTN","article-title":"Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions","volume":"143","author":"Pham-Ledard","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.det.2019.05.004_bib56","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/hupa.2002.126881","article-title":"Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity","volume":"33","author":"Paulli","year":"2002","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.det.2019.05.004_bib57","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood-2003-08-2726","article-title":"Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas","volume":"103","author":"Grange","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.det.2019.05.004_bib58","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.det.2019.05.004_bib59","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.1998.16.6.2080","article-title":"bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related","volume":"16","author":"Geelen","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.det.2019.05.004_bib60","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/PAS.0b013e3181e5060a","article-title":"IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma","volume":"34","author":"Koens","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.det.2019.05.004_bib61","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.004_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000294963","article-title":"Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type","volume":"123","author":"Kobold","year":"2010","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.det.2019.05.004_bib63","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent outcome of immunomodulation or Bruton\u2019s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ejh.12315","article-title":"Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas","volume":"93","author":"Fabbri","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.det.2019.05.004_bib65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0609.2008.01197.x","article-title":"Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies","volume":"82","author":"Pulini","year":"2009","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.det.2019.05.004_bib66","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid\u00ae (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"10.1016\/j.det.2019.05.004_bib67","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.det.2019.05.004_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2018.03.1516","article-title":"A\u00a0single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type","author":"Beylot-Barry","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","article-title":"Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the \u2018cutaneous variant","volume":"127","author":"Ferreri","year":"2004","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2010.08354.x","article-title":"Molecular analysis of intravascular large B-cell lymphoma with neoangiogenesis","volume":"152","author":"Saurel","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib71","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2006-01-021253","article-title":"Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5","volume":"109","author":"Murase","year":"2007","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.det.2019.05.004_bib72","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1200\/JCO.2008.19.1841","article-title":"Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?","volume":"26","author":"Ferreri","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.det.2019.05.004_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2141.2008.07338.x","article-title":"The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in \u2018Western\u2019 patients with intravascular large B-cell lymphoma","volume":"143","author":"Ferreri","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.det.2019.05.004_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3960\/jslrt.48.25","article-title":"Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma","volume":"48","author":"Shimada","year":"2008","journal-title":"J\u00a0Clin Exp Hematop"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:45:53Z","timestamp":1760006753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863519300464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0733863519300464"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2019.05.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"type":"print","value":"0733-8635"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Cutaneous B-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}